CPDC Celebrates Successful FDA Inspection!

August 23, 2019 CPDC
« 1 of 6 »

Hamilton, Ontario, August 16, 2019 – The Centre for Probe Development and Commercialization’s Senior Leadership Team took time on Friday afternoon to celebrate with their Hamilton staff on the McMaster University campus at the famous Willy Dog Hot Dog cart. Over 60 staff attended the lunch time event on a great summer day!  The event was held to show appreciation to our staff for the effort put into the preparation for CPDC’s FDA audit held in July 2019. Special treats were sent to our offsite locations in Toronto and Ottawa, as well as to the night shift staff in Hamilton, to ensure the whole company was included in the event.

CPDC’s President and CEO, Dr. Joe McCann commented at the event that “CPDC is committed to maintaining industry leading quality standards and implementing continued quality improvements. We are very grateful and appreciative of our staff who all embrace this approach and who put significant effort into the preparation for the audit.  We are extremely pleased to announce that no observations were received at the conclusion of the inspection.  CPDC extends its gratitude to our clients who supported us during the inspection.” CPDC is also inspected by Health Canada and has maintained a compliant rating since 2009.

About CPDC

The Centre for Probe Development and Commercialization (CPDC) is a private, not-for-profit company “Dedicated to improving patient’s lives by advancing drugs for the diagnosis and treatment of diseases.”  Created in 2008, with the support of multiple stakeholders, including the Networks of Centres of Excellence (NCE), McMaster University and the Ontario Institute for Cancer Research (OICR), CPDC has become a global leader in the discovery, development and commercialization of next-generation radiopharmaceuticals. With an established a pipeline of products and a robust and reliable manufacturing unit, CPDC supplies innovative diagnostic and therapeutic radiopharmaceuticals that are used daily in Canada and around the world. CPDC currently employs over 110 staff in Hamilton, Toronto and Ottawa. For more information about CPDC, please visit: www.imagingprobes.ca

Contacts

Centre for Probe Development and Commercialization

Angela Lauretani, 905 525-9140, ext. 21212

cpdc@imagingprobes.ca

More news from CPDC

Chuck Conroy Appointed CEO of ARTMS

VANCOUVER, British Columbia–ARTMS Products Inc., the global leader in the innovation and commercialization of novel technologies that enable cyclotron production of the world’s most needed medical radioisotopes, is pleased to announce the appointment of Charles S. Conroy R.Ph, MBA as its Chief Executive Officer. Mr. Conroy brings to ARTMS more than 25 years of experience

ARTMS Products Received $1.5 Million of Funding from the Federal Government

VANCOUVER, British Columbia–ARTMS Products Inc., a global leader in the development and commercialization of novel technologies and products that enable cyclotron production of the world’s most needed medical radioisotopes, is pleased to announce they have received $1.5 million funding from Western Economic Diversification Canada as part of its Business Scale-up and Productivity program. The federal

CPDC joins forces with the Canadian Nuclear Isotope Council

Hamilton, Ontario, February 19, 2019 – As Canada strives to maintain a leadership position in science and technology, the Centre for Probe Development and Commercialization (CPDC), located at McMaster University, has partnered with the Canadian Nuclear Isotope Council (CNIC) to ensure Canada remains at the forefront of medical isotope R&D and production, and to advocate

For more information contact us at: